Showing 5101-5110 of 21466 results for "".
- Platelet-Rich Plasma vs Corticosteroids and NSAIDs in Knee Osteoarthritishttps://reachmd.com/news/platelet-rich-plasma-corticosteroids-nsaids-knee-osteoarthritis/2487664/Key Takeaways Platelet-rich plasma was associated with better pain scores and WOMAC outcomes than corticosteroid injection and oral NSAID treatment at follow-up. Opioid use was lower with platelet-rich plasma at 3 months than with both control groups a
- Combined Lower Blepharoplasty and PDO Thread Lift Shows Early Promise in Case Serieshttps://reachmd.com/news/combined-lower-blepharoplasty-and-pdo-thread-lift-shows-early-promise-in-case-series/2487655/A combined transcutaneous lower blepharoplasty and multi-directional polydioxanone (PDO) thread midface lift performed through a shared subciliary incision demonstrated favorable early aesthetic outcomes with no reported major complications in a prospective consecutive case series published in
- AI Chest X-Ray Prioritization Did Not Shorten Lung Cancer Pathwayhttps://reachmd.com/news/ai-chest-x-ray-prioritization-did-not-shorten-lung-cancer-pathway/2487646/Key Takeaways Immediate AI prioritization was not associated with shorter time to CT or lung cancer diagnosis. Secondary pathway outcomes were also similar, including urgent referral timing, treatment timing, stage at diagnosis, and lung cancer inciden
- Embedded Primary Care in Adult Sickle Cell Teamshttps://reachmd.com/news/embedded-primary-care-in-adult-sickle-cell-teams/2487650/Key Takeaways The embedded model was associated with higher odds of several general preventive and sickle cell-specific care measures. Among patients who saw the embedded clinician, annual outpatient visits increased from 2.7 to 4.2 per year.
- FDA Grants SKYRIZI Approval to Children With Plaque Psoriasis and PsAhttps://reachmd.com/news/fda-expands-skyrizi-approval-to-include-children-with-plaque-psoriasis-and-psoriatic-arthritis/2487657/The FDA has expanded the indication for SKYRIZI® (risankizumab-rzaa) to include children aged 6 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, according to an announcement from AbbVie.
- Nociception-Guided Opioids In Laparoscopic Endometriosis Surgeryhttps://reachmd.com/news/nociception-guided-opioids-in-laparoscopic-endometriosis-surgery/2487647/Key Takeaways Perioperative opioid consumption was similar between NOL-guided analgesia and standard care within the standardized multimodal protocol. Postoperative pain scores were comparable at all reported time points, and no improvement in early po
- Radiofrequency Microneedling Shows Promise for Periorbital Skin Rejuvenationhttps://reachmd.com/news/radiofrequency-microneedling-shows-promise-for-periorbital-skin-rejuvenation/2487641/Radiofrequency microneedling (RFMN) demonstrated favorable safety and modest clinical improvements in periorbital skin rejuvenation in a prospective, evaluator-blinded clinical study published in the Journal of Cosmetic and Laser Therapy. Prospective Study Evaluates RFMN f
- Dupilumab Shows Histologic Benefit in Eosinophilic Gastritis Trialhttps://reachmd.com/news/dupilumab-histologic-benefit-eosinophilic-gastritis/2487633/Key Takeaways Dupilumab was associated with greater week 12 improvement in the primary gastric histologic endpoint than placebo. Prespecified secondary histologic and endoscopic measures, including EoS-HSS, mean gastric eosinophil count, and EoG-REFS,
- Oncologist Preferences in First-Line Alk-Positive Metastatic NSCLChttps://reachmd.com/news/oncologist-preferences-in-first-line-alk-positive-metastatic-nsclc/2487572/Key Takeaways U.S. oncologists were asked to weigh several attributes of first-line ALK-targeted therapy in metastatic ALK-positive NSCLC. The choice-task attributes included efficacy, intracranial activity, safety, dosing convenience, and cost or cove
- FDA Expands ZORYVE Cream Approval to Children as Young as 2 Years With Plaque Psoriasishttps://reachmd.com/news/fda-expands-zoryve-cream-approval-to-children-as-young-as-2-years-with-plaque-psoriasis/2487622/The US Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) expanding the indication for ZORYVE (roflumilast) cream 0.3% to include the topical treatment of plaque psoriasis, including intertriginous areas, in children as young as 2 yea